Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
17
NBIO Quote, Financials, Valuation and Earnings
Last price:
$0.0000
Seasonality move
:
-14.96%
Day range:
$0.0002 - $0.0002
52-week range:
$0.0000 - $0.1345
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
1.9K
Avg. volume:
41.2K
1-year change:
-99.6%
Market cap:
$34.4K
Revenue:
--
EPS (TTM):
-$0.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NBIO
Nascent Biotech, Inc.
|
-- | -- | -- | -- | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NBIO
Nascent Biotech, Inc.
|
$0.0002 | -- | $34.4K | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.75 | $0.85 | $598.6M | 7.98x | $0.80 | 0% | 9.23x |
|
NNVC
NanoViricides, Inc.
|
$1.19 | $6.50 | $21.4M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.84 | $2.00 | $687.2K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.6M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NBIO
Nascent Biotech, Inc.
|
-- | 41.551 | -- | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NBIO
Nascent Biotech, Inc.
|
-- | -$375.7K | -- | -- | -- | -$324.7K |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Nascent Biotech, Inc. vs. Competitors
-
Which has Higher Returns NBIO or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Nascent Biotech, Inc.'s net margin of -255.85%. Nascent Biotech, Inc.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital NBIONascent Biotech, Inc.-- -$0.00 -- NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About NBIO or NBY?
Nascent Biotech, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.11%. Given that NovaBay Pharmaceuticals, Inc. has higher upside potential than Nascent Biotech, Inc., analysts believe NovaBay Pharmaceuticals, Inc. is more attractive than Nascent Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBIONascent Biotech, Inc.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is NBIO or NBY More Risky?
Nascent Biotech, Inc. has a beta of 1.550, which suggesting that the stock is 55.013% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock NBIO or NBY?
Nascent Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Nascent Biotech, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBIO or NBY?
Nascent Biotech, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Nascent Biotech, Inc.'s net income of -$377.4K is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Nascent Biotech, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nascent Biotech, Inc. is -- versus 9.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBIONascent Biotech, Inc.-- -- -- -$377.4K NBYNovaBay Pharmaceuticals, Inc.9.23x 7.98x $521K -$1.3M
-
Which has Higher Returns NBIO or NNVC?
NanoViricides, Inc. has a net margin of -- compared to Nascent Biotech, Inc.'s net margin of --. Nascent Biotech, Inc.'s return on equity of -- beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital NBIONascent Biotech, Inc.-- -$0.00 -- NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About NBIO or NNVC?
Nascent Biotech, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 446.22%. Given that NanoViricides, Inc. has higher upside potential than Nascent Biotech, Inc., analysts believe NanoViricides, Inc. is more attractive than Nascent Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBIONascent Biotech, Inc.0 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is NBIO or NNVC More Risky?
Nascent Biotech, Inc. has a beta of 1.550, which suggesting that the stock is 55.013% more volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock NBIO or NNVC?
Nascent Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nascent Biotech, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBIO or NNVC?
Nascent Biotech, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Nascent Biotech, Inc.'s net income of -$377.4K is higher than NanoViricides, Inc.'s net income of -$1.8M. Notably, Nascent Biotech, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nascent Biotech, Inc. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBIONascent Biotech, Inc.-- -- -- -$377.4K NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns NBIO or OGEN?
Oragenics, Inc. has a net margin of -- compared to Nascent Biotech, Inc.'s net margin of --. Nascent Biotech, Inc.'s return on equity of -- beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital NBIONascent Biotech, Inc.-- -$0.00 -- OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About NBIO or OGEN?
Nascent Biotech, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 139.49%. Given that Oragenics, Inc. has higher upside potential than Nascent Biotech, Inc., analysts believe Oragenics, Inc. is more attractive than Nascent Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBIONascent Biotech, Inc.0 0 0 OGENOragenics, Inc.1 0 0 -
Is NBIO or OGEN More Risky?
Nascent Biotech, Inc. has a beta of 1.550, which suggesting that the stock is 55.013% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock NBIO or OGEN?
Nascent Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nascent Biotech, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBIO or OGEN?
Nascent Biotech, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Nascent Biotech, Inc.'s net income of -$377.4K is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Nascent Biotech, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nascent Biotech, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBIONascent Biotech, Inc.-- -- -- -$377.4K OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns NBIO or PTN?
Palatin Technologies has a net margin of -- compared to Nascent Biotech, Inc.'s net margin of --. Nascent Biotech, Inc.'s return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NBIONascent Biotech, Inc.-- -$0.00 -- PTNPalatin Technologies-- -- -- -
What do Analysts Say About NBIO or PTN?
Nascent Biotech, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Nascent Biotech, Inc., analysts believe Palatin Technologies is more attractive than Nascent Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBIONascent Biotech, Inc.0 0 0 PTNPalatin Technologies0 0 0 -
Is NBIO or PTN More Risky?
Nascent Biotech, Inc. has a beta of 1.550, which suggesting that the stock is 55.013% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock NBIO or PTN?
Nascent Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nascent Biotech, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBIO or PTN?
Nascent Biotech, Inc. quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of --. Nascent Biotech, Inc.'s net income of -$377.4K is higher than Palatin Technologies's net income of --. Notably, Nascent Biotech, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nascent Biotech, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBIONascent Biotech, Inc.-- -- -- -$377.4K PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns NBIO or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Nascent Biotech, Inc.'s net margin of --. Nascent Biotech, Inc.'s return on equity of -- beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital NBIONascent Biotech, Inc.-- -$0.00 -- TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About NBIO or TOVX?
Nascent Biotech, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3497.12%. Given that Theriva Biologics, Inc. has higher upside potential than Nascent Biotech, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Nascent Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBIONascent Biotech, Inc.0 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is NBIO or TOVX More Risky?
Nascent Biotech, Inc. has a beta of 1.550, which suggesting that the stock is 55.013% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock NBIO or TOVX?
Nascent Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nascent Biotech, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBIO or TOVX?
Nascent Biotech, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Nascent Biotech, Inc.'s net income of -$377.4K is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Nascent Biotech, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nascent Biotech, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBIONascent Biotech, Inc.-- -- -- -$377.4K TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
